STAT3 polymorphism can predict the response to interferon-α therapy in patients with metastatic renal cell carcinoma.

[1]  P. Carmeliet,et al.  VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. , 2012, The Lancet. Oncology.

[2]  M. Climent,et al.  Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. , 2011, The Lancet. Oncology.

[3]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[4]  R. Figlin,et al.  The high-dose aldesleukin (HD IL-2) "SELECT" trial in patients with metastatic renal cell carcinoma (mRCC). , 2010 .

[5]  T. Miki,et al.  A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. , 2010, Japanese journal of clinical oncology.

[6]  Y. Tomita,et al.  Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. , 2010, European urology.

[7]  Katsuaki Sato,et al.  Selective Expansion of Foxp3-Positive Regulatory T Cells and Immunosuppression by Suppressors of Cytokine Signaling 3-Deficient Dendritic Cells1 , 2007, The Journal of Immunology.

[8]  Naoko Kinukawa,et al.  STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Mccarroll,et al.  Copy-number variation and association studies of human disease , 2007, Nature Genetics.

[10]  S. Horie,et al.  Prevalence of renal cell carcinoma: A nation‐wide survey in Japan, 2002 , 2007, International journal of urology : official journal of the Japanese Urological Association.

[11]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[12]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[13]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[14]  Y. Kawakami,et al.  The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells , 2006, The Journal of experimental medicine.

[15]  E. Eisenhauer,et al.  RECIST revisited: a review of validation studies on tumour assessment. , 2006, European journal of cancer.

[16]  Satoru Fukuyama,et al.  Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor–β1 , 2006, The Journal of experimental medicine.

[17]  Hua Yu,et al.  Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.

[18]  N. Sebire,et al.  Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein , 2005, The Journal of experimental medicine.

[19]  S. Signoretti,et al.  Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer , 2005, Clinical Cancer Research.

[20]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[21]  B. Foxwell,et al.  Signal Transducer and Activator of Transcription 3 Is the Dominant Mediator of the Anti-Inflammatory Effects of IL-10 in Human Macrophages , 2004, The Journal of Immunology.

[22]  R. Figlin,et al.  Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma , 2003, Cancer.

[23]  J. Hirschhorn,et al.  A comprehensive review of genetic association studies , 2002, Genetics in Medicine.

[24]  T. M. Hsu,et al.  Genotyping single-nucleotide polymorphisms by the invader assay with dual-color fluorescence polarization detection. , 2001, Clinical chemistry.

[25]  S. Akira,et al.  STAT family of transcription factors in cytokine-mediated biological responses. , 2000, Cytokine & growth factor reviews.

[26]  Roy Garcia,et al.  STATs in oncogenesis , 2000, Oncogene.

[27]  J. Darnell.  STATs and gene regulation. , 1997, Science.

[28]  Hua Yu,et al.  Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.

[29]  Hua Yu,et al.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.

[30]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .